This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Madrigal Pharmaceuticals, Inc.

Drug Names(s): STA-9090

Description: STA-9090 is a novel, injectable, synthetic, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a chaperone protein that regulates the activity of numerous signaling proteins, in particular kinase proteins, that trigger uncontrolled proliferation in cancer cells. STA-9090 was developed internally by Synta using the Company's internal chemistry and drug optimization expertise to invent a novel chemical structure unrelated to the ansamycin family of Hsp90 inhibitors such as 17-AAG.

Ganetespib News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug